IMIZOL®
(imidocarb dipropionate)
Product Description
A sterile solution containing imidocarb dipropionate for the treatment of dogs with clinical signs of babesiosis and/or demonstrated Babesia organisms in the blood.
Indications
For the treatment of dogs with clinical signs of babesiosis and/or demonstrated Babesia organisms in the blood.
Features and Benefits
- Two treatments two weeks apart
- Simplifies treatment regimen
- Injectable administration keeps the treatment under your control
- Eliminates the issue of treatment compliance
- Intramuscular or subcutaneous administration
- Provides more versatility
- Low volume dose treatment (3mg/lb), 100 lb dog requires only 2.5 mL of IMIZOL per injection. Makes it cost effective and practical.
Important Safety Information
NOT FOR HUMAN USE. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. MUST NOT BE ADMINISTERED INTRAVENOUSLY. The safety and effectiveness of imidocarb have not been determined in puppies or in breeding, lactating, or pregnant animals. Risk versus benefit should be considered before using this drug in dogs with impaired lung, liver, or kidney function. Do not use this product simultaneously with exposure to cholinesterase inhibiting drugs, pesticides, or chemicals. For complete safety information, refer to product label and Merck Animal Health website.
For additional information, please see the product label.
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global